# Nkarta

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nkarta

- Industry: Healthcare Specialists
- Headquarters: San Francisco, US
- Website: www.nkartatx.com/
- Total disclosed funding: $44M
- Latest round: Series B (Aug 27, 2019)
- Investors on record: 9

## About

Based in California, US, and founded in 2015, Nkarta, Inc. operates as a provider of advanced cell therapies, such as engineered Natural Killer (NK) cells, to improve cancer treatment across diverse patient populations. In March 2024, Nkarta, Inc. raised USD 240 million in PIPE funding from Adage Capital Management, Boxer Capital, Commodore Capital, Cormorant Asset Management, EcoR1 Capital, Janus Henderson Investors, OrbiMed Advisors, and Ridgeback Asset Management, Deerfield Management, RA Capital Management, Samsara BioCapital, and SR One. As part of the transaction, the company agreed to sell 21.01 million shares of common stock and pre-fund warrants to purchase 3.0 million shares of common stock for USD 240 million at USD 9.9 per share. As of 2024, the company is led by its CEO, Paul Hastings. The firm trades on NAS (NASDAQ) under the ticker symbol NKTX.

The company provides a wide range of biotechnological solutions, such as engineered NK cell therapies designed to target and destroy tumor cells efficiently. Additionally, the firm also provides services such as developing robust immunotherapies without genetic alteration.

## Funding rounds

- Series B, Aug 27, 2019, $44M — New Enterprise Associates, EQT Life Sciences, SR One, Amgen Ventures, Novo Holdings, Deerfield Management, RA Capital Management, Samsara BioCapital, Logos Capital

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series B
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series B
- SR One (https://capitalatlas.ai/funds/sr-one) — Series B
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series B
- Novo Holdings — Series B
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series B
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series B